Sign up to save your podcasts
Or
Share Retatrutide weight loss rivals bariatric surgery
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Retatrutide weight loss rivals bariatric surgery
Beyond Ozempic: Eli Lilly’s Retatrutide Hits 30% Weight Loss | The End of Bariatric Surgery?
Is the era of weight-loss surgery coming to an end? In today’s episode, we break down the explosive results of the Phase 3 TRIUMPH-1 trial for Eli Lilly’s next-generation drug, Retatrutide. We analyze how this "Triple G" injectable—which targets GLP-1, GIP, and glucagon receptors—helped patients lose an average of 28.3% of their body weight (over 70 lbs) in 80 weeks, with the heaviest participants reaching a staggering 30.3% loss.
We dive into why experts are calling this a "game changer" that rivals gastric bypass surgery. We also explore the surprising data on the 4mg low dose, which offered high efficacy with a tolerability profile even better than the placebo. Plus, we discuss the side effects—from nausea to the rare nerve sensation known as dysesthesia—and what this means for the global $100 billion obesity market as Lilly races against Novo Nordisk. If you want to understand the future of metabolic health, this is the episode you can't miss.
This episode includes AI-generated content.
Is the era of weight-loss surgery coming to an end? In today’s episode, we break down the explosive results of the Phase 3 TRIUMPH-1 trial for Eli Lilly’s next-generation drug, Retatrutide. We analyze how this "Triple G" injectable—which targets GLP-1, GIP, and glucagon receptors—helped patients lose an average of 28.3% of their body weight (over 70 lbs) in 80 weeks, with the heaviest participants reaching a staggering 30.3% loss.
We dive into why experts are calling this a "game changer" that rivals gastric bypass surgery. We also explore the surprising data on the 4mg low dose, which offered high efficacy with a tolerability profile even better than the placebo. Plus, we discuss the side effects—from nausea to the rare nerve sensation known as dysesthesia—and what this means for the global $100 billion obesity market as Lilly races against Novo Nordisk. If you want to understand the future of metabolic health, this is the episode you can't miss.
This episode includes AI-generated content.
View all episodes
By @LocutorCoBeyond Ozempic: Eli Lilly’s Retatrutide Hits 30% Weight Loss | The End of Bariatric Surgery?
Is the era of weight-loss surgery coming to an end? In today’s episode, we break down the explosive results of the Phase 3 TRIUMPH-1 trial for Eli Lilly’s next-generation drug, Retatrutide. We analyze how this "Triple G" injectable—which targets GLP-1, GIP, and glucagon receptors—helped patients lose an average of 28.3% of their body weight (over 70 lbs) in 80 weeks, with the heaviest participants reaching a staggering 30.3% loss.
We dive into why experts are calling this a "game changer" that rivals gastric bypass surgery. We also explore the surprising data on the 4mg low dose, which offered high efficacy with a tolerability profile even better than the placebo. Plus, we discuss the side effects—from nausea to the rare nerve sensation known as dysesthesia—and what this means for the global $100 billion obesity market as Lilly races against Novo Nordisk. If you want to understand the future of metabolic health, this is the episode you can't miss.
This episode includes AI-generated content.
Is the era of weight-loss surgery coming to an end? In today’s episode, we break down the explosive results of the Phase 3 TRIUMPH-1 trial for Eli Lilly’s next-generation drug, Retatrutide. We analyze how this "Triple G" injectable—which targets GLP-1, GIP, and glucagon receptors—helped patients lose an average of 28.3% of their body weight (over 70 lbs) in 80 weeks, with the heaviest participants reaching a staggering 30.3% loss.
We dive into why experts are calling this a "game changer" that rivals gastric bypass surgery. We also explore the surprising data on the 4mg low dose, which offered high efficacy with a tolerability profile even better than the placebo. Plus, we discuss the side effects—from nausea to the rare nerve sensation known as dysesthesia—and what this means for the global $100 billion obesity market as Lilly races against Novo Nordisk. If you want to understand the future of metabolic health, this is the episode you can't miss.
This episode includes AI-generated content.